CancerConsultants provides summaries of new treatment strategies as they are discovered and reported by cancer physicians around the world. Our medical staff attends medical meetings worldwide and reviews medical literature daily to ensure appropriate news is provided to cancer patients and their families in a timely manner.
News of the results of recent clinical trials evaluating cancer therapies and supportive care strategies serve to educate patients regarding new treatment strategies for cancer and facilitate discussions with their doctor. Development of new cancer treatments usually begins in patients with recurrent or metastatic cancers. Once the new treatment appears effective, it is applied to earlier stages of the disease or to patients at higher risk of treatment failure.
Comprehensive Study of Esophageal Cancer Reveals Several Molecular Subtypes, Provides New Insight into Increasingly Prevalent Disease (January 16, 2017)
A comprehensive analysis of 559 esophageal and gastric cancer samples, collected from patients around the world, suggests the two main types of esophageal cancer differ markedly in their molecular characteristics... Continue Reading
One in every six colorectal cancer patients (16 percent) diagnosed under age 50 has at least one inherited genetic mutation that increases his or her cancer risk and many of these mutations could go undetected... Continue Reading
Gradalis, Inc. a clinical stage cellular immunotherapy company, developing Vigil® Engineered Autologous Tumor Cell (EATC) therapy, announced that it has entered into a collaboration agreement with Genentech,... Continue Reading
Women diagnosed with breast cancer have greater rates of survival and lower rates of disease recurrences if they have more social ties, compared to women who are more socially isolated. These results were... Continue Reading
The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer... Continue Reading
CTI BioPharma Corp. announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug... Continue Reading
According to the American Society for Radiation Oncology (ASTRO) younger patients with early stage breast cancer and individuals with low-risk ductal carcinoma in situ (DCIS) can appropriately be treated... Continue Reading
Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan®... Continue Reading
Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine... Continue Reading
The Alliance for the Adoption of Innovations in Medicine (Aimed Alliance) released the results of a poll showing that Americans value innovative treatments, are willing to pay more for them, and do not... Continue Reading